1.

P440 First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)

1.

P527 Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn’s disease from a Belgian registry

1.

P496 Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study

1.

P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Disea...

1.

DOP057. Tailored step-up approach results in beneficial long-term disease outcome in the prospective Belgian registry of paediatric Crohn’s disease (BELCRO)

1.

P153. Type of treating physician is associated with long-term disease outcome in the prospective Belgian paediatric Crohn’s disease registry

1.

P732 Clinical characteristics of inflammatory bowel disease in Belgian immigrants from Moroccan and Caucasian origin

1.

DOP003 Ustekinumab induces clinical and biological remission in biologic refractory Crohn’s disease patients: A real-world belgian cohort study

1.

P723 Effectiveness and persistence of vedolizumab in patients with Inflammatory bowel Disease: Results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)

1.

P131 Effectiveness and safety of vedolizumab maintenance therapy for inflammatory bowel disease: findings from a Belgian registry